for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion



This open-label study is to assess the safety of continued treatment with Relamorelin for participants who previously completed the RLM-MD-03 or RLM-MD-04 study and to provide treatment for these participants until Relamorelin becomes commercially available or the Sponsor terminates development.

Official Title

Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis


Gastroparesis Diabetic Gastroparesis Relamorelin 10 μg


You can join if…

Open to people ages 18 years and up

  • Successful completion of either Study RLM-MD-03 or Study RLM-MD-04
  • Ability to provide written IC prior to any study procedures and willingness and ability to comply with study procedures
  • Demonstration of adequate compliance with the study procedures in Study RLM-MD-03 or RLM-MD-04, in the opinion of the investigator

You CAN'T join if...

  • Participant is planning to receive an investigational drug (other than study intervention) or investigational device at any time during Study 3071-305-020.
  • Participant has an unresolved AE from a lead-in study, ie, a clinically significant finding on physical examination, clinical laboratory test, or 12-lead ECG that, in the investigator's opinion, would limit the participant's ability to participate in or complete the study.
  • Any other reason that, in the investigator's opinion, would confound proper interpretation of the study or expose a participant to unacceptable risk, including renal, hepatic, or cardiopulmonary disease
  • Females who are pregnant, nursing, or planning a pregnancy during the study


  • University of California San Diego not yet accepting patients
    La Jolla California 92037 United States
  • Medical Associates Research Group, Inc not yet accepting patients
    San Diego California 92123 United States
  • Clinical Applications Laboratories, Inc. not yet accepting patients
    San Diego California 92103 United States


accepting new patients
Start Date
Completion Date
Phase 3
Study Type
Last Updated